Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1066653

Mycobacterium tuberculosis infection among patients with inflammatory bowel disease under biologics: experience of Croatian Tertiary Centre


Ogresta Doris, Bišćanin Alen, Tomašić Vedran, Dorosulić Zdravko, Kralj Dominik, Forgač Jelena, Ćaćić Petra, Lerotić Ivan, Hrabar Davor
Mycobacterium tuberculosis infection among patients with inflammatory bowel disease under biologics: experience of Croatian Tertiary Centre // JOURNAL OF CROHN’S AND COLITIS International Journal Devoted to Inflammatory Bowel Diseases Official Journal of the European Crohn’s and Colitis Organisation / Egan J. Laurence (ur.).
Vienna, Austria: Oxford University Press (OUP), 2020. str. S672-S709 doi:10.1093/ecco-jcc/jjz203 (poster, međunarodna recenzija, sažetak, ostalo)


CROSBI ID: 1066653 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Mycobacterium tuberculosis infection among patients with inflammatory bowel disease under biologics: experience of Croatian Tertiary Centre

Autori
Ogresta Doris, Bišćanin Alen, Tomašić Vedran, Dorosulić Zdravko, Kralj Dominik, Forgač Jelena, Ćaćić Petra, Lerotić Ivan, Hrabar Davor

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo

Izvornik
JOURNAL OF CROHN’S AND COLITIS International Journal Devoted to Inflammatory Bowel Diseases Official Journal of the European Crohn’s and Colitis Organisation / Egan J. Laurence - Vienna, Austria : Oxford University Press (OUP), 2020, S672-S709

Skup
15th Congress of ECCO - European Crohn's and Colitis Organisation

Mjesto i datum
Beč, Austrija, 12-15.02.2020

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
IBD, TBC, biologics

Sažetak
Background: Mycobacterium tuberculosis infection (TB) causes a huge number of deaths in the world. A majority (95%) of infections remain asymptomatic, defined as latent tuberculosis (LTB). The estimated incidence rate of TB in Croatia is 10.6 cases per 100 000 inhabitants. Patients with inflammatory bowel diseases (IBD) usually require immunosuppressive therapies which puts them at higher risk for infection. LTB diagnosis and prophylactic treatment are recommended for all patients starting biologics. Methods: A single-centre retrospective study in the continental part of Croatia included all IBD patients who started treatment with biologics and have presented with TB or LTB from January 2016 till September 2019. The aim was to evaluate the prevalence of LTB among patients with IBD before starting biologic therapy, and TB reactivation during treatment with biologics. All patients underwent Interferon Gamma Release Assay (IGRA) and X-ray. Active infection was excluded or diagnosed using clinical history, bronchoscopy, CT scan and sputum stain for Mycobacteria. Results: Study population included 74 patients treated with biologics: 51% female, 73% Crohn’s disease (CD) ; 37% starting adalimumab, 29% infliximab, 19% ustekinumab and 15% vedolizumab. Prevalence of LTB was 8.1% (6 patients), and all patients underwent isoniazid prophylaxis for 9 months except one patient treated with conventional immunomodulatory therapy which failed prophylactic therapy with both isoniazid and rifampin (liver injury). Among patients with adequate chemoprophylaxis, two patients later on started with anti-TNF therapy (adalimumab), two patients with vedolizumab and one with ustekinumab. One patient with CD and negative LTB screening developed pulmonary TB during induction with infliximab (1 month after initiation) ; after successful treatment with conventional fourfold therapy, the patient was switched to vedolizumab. During the observational period (median 16 months), all IBD patients with LTB as well with cured TB were in clinical and biochemical remission, without signs of TB (re)activation. Conclusion: Our study has demonstrated that prevalence of LTB among our IBD patients starting biologics was significant (8.1%). Treatment with vedolizumab, ustekinumab and anti-TNF (adalimumab) after isoniazid chemoprophylaxis appears to be safe during the observational period, without signs of TB reactivation.

Izvorni jezik
Engleski



POVEZANOST RADA


Profili:

Avatar Url Alen Bišćanin (autor)

Avatar Url Ivan Lerotić (autor)

Avatar Url Davor Hrabar (autor)

Avatar Url Petra Ćaćić (autor)

Avatar Url Vedran Tomašić (autor)

Citiraj ovu publikaciju

Ogresta Doris, Bišćanin Alen, Tomašić Vedran, Dorosulić Zdravko, Kralj Dominik, Forgač Jelena, Ćaćić Petra, Lerotić Ivan, Hrabar Davor
Mycobacterium tuberculosis infection among patients with inflammatory bowel disease under biologics: experience of Croatian Tertiary Centre // JOURNAL OF CROHN’S AND COLITIS International Journal Devoted to Inflammatory Bowel Diseases Official Journal of the European Crohn’s and Colitis Organisation / Egan J. Laurence (ur.).
Vienna, Austria: Oxford University Press (OUP), 2020. str. S672-S709 doi:10.1093/ecco-jcc/jjz203 (poster, međunarodna recenzija, sažetak, ostalo)
Ogresta Doris, Bišćanin Alen, Tomašić Vedran, Dorosulić Zdravko, Kralj Dominik, Forgač Jelena, Ćaćić Petra, Lerotić Ivan, Hrabar Davor (2020) Mycobacterium tuberculosis infection among patients with inflammatory bowel disease under biologics: experience of Croatian Tertiary Centre. U: Egan J. Laurence (ur.)JOURNAL OF CROHN’S AND COLITIS International Journal Devoted to Inflammatory Bowel Diseases Official Journal of the European Crohn’s and Colitis Organisation doi:10.1093/ecco-jcc/jjz203.
@article{article, year = {2020}, pages = {S672-S709}, DOI = {10.1093/ecco-jcc/jjz203}, keywords = {IBD, TBC, biologics}, doi = {10.1093/ecco-jcc/jjz203}, title = {Mycobacterium tuberculosis infection among patients with inflammatory bowel disease under biologics: experience of Croatian Tertiary Centre}, keyword = {IBD, TBC, biologics}, publisher = {Oxford University Press (OUP)}, publisherplace = {Be\v{c}, Austrija} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font